Mycophenolate Mofetil in Combination with Steroids for Treatment of C3 Glomerulopathy: A Case Series

Avasare R. S., Canetta P. A., Bomback A. S., Marasa M., Caliskan Y. K., Ozluk Y., ...Daha Fazla

CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, cilt.13, sa.3, ss.406-413, 2018 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 13 Sayı: 3
  • Basım Tarihi: 2018
  • Doi Numarası: 10.2215/cjn.09080817
  • Dergi Adı: CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.406-413
  • Anahtar Kelimeler: glomerular disease, complement, mycophenolate mofetil, Humans, Mycophenolic Acid, creatinine, Complement Membrane Attack Complex, Retrospective Studies, Follow-Up Studies, Universities, Immunosuppressive Agents, glomerulonephritis, proteinuria, immunosuppression, Recurrence, Registries, HEMOLYTIC-UREMIC SYNDROME, DENSE DEPOSIT DISEASE, COMPLEMENT FACTOR-H, MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS, ECULIZUMAB, MUTATIONS, ACTIVATION, CFHR5
  • İstanbul Üniversitesi Adresli: Evet

Özet

Background and objectives C3 glomerulopathy is a form of complement-mediated GN. Immunosuppressive therapy may be beneficial in the treatment of C3 glomerulopathy. Mycophenolate mofetil is an attractive treatment option given its role in the treatment of other complement-mediated diseases and the results of the Spanish Group for the Study of Glomerular Diseases C3 Study. Here, we study the outcomes of patients with C3 glomerulopathy treated with steroids and mycophenolate mofetil.